Evaluation of dose‐dependent treatment effects after mid‐trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's disease

INTRODUCTION: While the Dominantly Inherited Alzheimer Network Trials Unit (DIAN‐TU) was ongoing, external data suggested higher doses were needed to achieve targeted effects; therefore, doses of gantenerumab were increased 5‐fold, and solanezumab was increased 4‐fold. We evaluated to what extent mi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Guoqiao, Li, Yan, Xiong, Chengjie, McDade, Eric, Clifford, David B., Mills, Susan L., Santacruz, Anna M., Aschenbrenner, Andrew J., Hassenstab, Jason, Benzinger, Tammie L.S., Gordon, Brian A., Fagan, Anne M., Coalier, Kelley A., Libre‐Guerra, Jorge J., McCullough, Austin, Joseph‐Mathurin, Nelly, Chen, Charles D., Mummery, Catherine, Wendelberger, Barbara A., Gauthier, Serge, Masellis, Mario, Holdridge, Karen C., Yaari, Roy, Chatterjee, Saptarshi, Sims, John, Delmar, Paul, Kerchner, Geoffrey A., Bittner, Tobias, Hofmann, Carsten, Bateman, Randall J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632865/
https://www.ncbi.nlm.nih.gov/pubmed/36348972
http://dx.doi.org/10.1002/dad2.12367

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632865/
https://www.ncbi.nlm.nih.gov/pubmed/36348972
http://dx.doi.org/10.1002/dad2.12367

Ejemplares similares